Takara Holdings and its consolidated subsidiary Takara Bio resolved to conclude a basic agreement, dated November 2, to transfer Takara Bio's GMP cell-processing contract business to S-RACMO by absorption-type company split, Takara Holdings said in a timely disclosure.
Steps still ahead
The definitive absorption split contract is scheduled for signing on November 16, and the transfer is scheduled to take effect on January 1, 2027. Because it is a simplified split, Takara Bio needs no shareholder meeting approval. S-RACMO plans to obtain its own shareholder approval by the day before the effective date.
What is not disclosed
The consideration was agreed between the two companies but is withheld under a confidentiality agreement. The assets and liabilities being transferred are also undisclosed, as are the results of the business itself, which the company cited contractual confidentiality and competitive reasons for withholding.
Why Takara Bio is leaving
Under the Takara Group Medium-Term Plan 2030, published in May 2026, Takara Bio set out to improve the earnings structure of its CDMO business by withdrawing from GMP cell-processing contract work. It says it will concentrate GMP manufacturing resources on nucleic acids and plasmids, proteins and enzymes, and viral vectors. The plan also includes a headcount reduction of a certain scale, efforts to secure employment opportunities for affected employees, consideration for technology and know-how, and sales of equipment.
S-RACMO is an existing contract developer and manufacturer for regenerative and cell medicine, owned 66.6% by Sumitomo Chemical and 33.4% by Sumitomo Pharma as of September 30, 2026.
Takara Holdings said the effect on its consolidated results is minor.